The management of bronchospasm in patients suffering from chronic obstructive pulmonary disease who require regular treatment with both ipratropium and salbutamol.
The FDA has announced the approval of Combivent Respimat (ipratropium bromide and albuterol sulfate) Inhalation Spray for patients with Chronic...
ATROVENT UDVs are indicated for treatment of reversible bronchospasm associated with chronic obstructive pulmonary disease (COPD). ATROVENT UDVs are indicated, when used concomitantly with inhaled beta 2 -agonists, for treatment of reversible airways obstruction as in acute and chronic asthma.
Boehringer Ingelheim announced that the FDA approved once-daily Stiolto Respimat (tiotropium bromide and olodaterol) Inhalation Spray as a long-term, once-daily...
The German Institute for Quality and Efficiency in Health Care (IQWiG) has examined in a dossier assessment whether the fixed-dose...
Boehringer Ingelheim has announced new data that show increase in FEV1 AUC0–12, a measure of lung function, with Stiolto Respimat...